In a press release from November 2023, the company announced that they were bringing lawsuits against two compounding pharmacies for selling adulterated and misbranded compounded drugs claiming to contain semaglutide. In a statement to Healthline, a Novo Nordisk representative said: To date, Novo Nordisk has filed a total of 12 legal actions against medical spas, weight loss or medical clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales of non-FDA approved compounded products claiming to contain semaglutide
Contact your clinician promptly for genital symptoms, painful urination, fever, unexpected weakness, or side effects that interfere with eating or hydration
Quality Control & Lot Documentation (CoA)
Thanks for reading, The Slim Transformation Team
This is especially important now that compound semaglutide is no longer a routine pathway and patients should transition to approved options when clinically appropriate